Company intelligence / Profile preview

Keryx Biopharmaceuticals, Inc.

Boston, Massachusetts, United Stateskeryx.org ↗

Ownership: Public · KERX
Development stage: Commercial

Overview

Keryx's lead product Auryxia (ferric citrate) was FDA approved for controlling serum phosphorus levels in CKD patients on dialysis and for treating iron deficiency anemia in adults with CKD not on dialysis.

Therapeutic areas: Nephrology
Modalities: Small moleculesiron-based compounds
Industry: Biotech

Drug pipeline

1 asset

ferric citrate

Commercial

Indications: Chronic kidney disease, Iron deficiency anemia

Partnerships

Japan Tobacco Inc.Torii Pharmaceutical Co., Ltd.Panion & BF Biotech, Inc.

Financials

Market cap: $0
Total revenue: $28M
Enterprise value: $106.2M

Beyond the preview

Go deeper on Keryx Biopharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Keryx Biopharmaceuticals, Inc..

Explore the full profile